Summary
India's pharmaceuticals secretary, Manoj Joshi, announced plans to revamp the bulk drug Production Linked Incentive (PLI) scheme. This initiative aims to address the country's reliance on imports for critical drugs, which creates strategic vulnerabilities and exposes the pharmaceutical supply chain to external disruptions and geopolitical risks.